GlassScriptPhysician profile
Mary Digiulio
NPI 1184835290
$2,350.72
in general payments reported to CMS, 2019-2025
28 companies · $786 in 2025
The $786 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $243 · 2023: $280 · 2024: $1,042 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.26 | 2022-2025 | Qulipta, Ubrelvy, Viberzi |
| Novo Nordisk INC | $351.37 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $249.11 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $184.60 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $120.08 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.41 | 2024-2025 | |
| Glaxosmithkline, LLC. | $99.93 | 2024-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.08 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $80.87 | 2022-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.33 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $65.14 | 2024-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $56.09 | 2024 | Vyepti, Rexulti |
| Xeris Pharmaceuticals, INC. | $54.65 | 2024-2025 | Gvoke Hypopen |
| Amgen INC. | $54.19 | 2024-2025 | Otezla, Repatha, Otezla |
| Inspire Medical Systems, INC. | $46.78 | 2024-2025 | Inspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44.10 | 2023-2024 | Veozah |
| Medtronic, INC. | $41.16 | 2023-2025 | Inceptiv, Accurian |
| Exact Sciences Corporation | $31.35 | 2023-2024 | Cologuard Collection Kit |
| Corium, LLC | $24.24 | 2024 | Azstarys |
| Antares Pharma, INC. | $23.42 | 2024 | Xyosted |
| Ironshore Pharmaceuticals INC. | $23.35 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.01 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $18.87 | 2025 | Eliquis |
| Sage Therapeutics, LLC | $18.39 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.10 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $15.45 | 2024 | Voquezna |
| Dexcom, INC. | $14.92 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Digiulio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.